STAAR SURGICAL CO (STAA) Stock Fundamental Analysis
USA - NASDAQ:STAA - US8523123052 - Common Stock
26.55 USD
-0.08 (-0.3%)
26.55 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to STAA. STAA was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While STAA has a great health rating, there are worries on its profitability. While showing a medium growth rate, STAA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year STAA has reported negative net income.
In the past year STAA has reported a negative cash flow from operations.
STAA had positive earnings in 4 of the past 5 years.
Each year in the past 5 years STAA had a positive operating cash flow.
1.2 Ratios
STAA has a Return On Assets (-21.76%) which is comparable to the rest of the industry.
With a Return On Equity value of -28.31%, STAA perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.76% | ||
| ROE | -28.31% | ||
| ROIC | N/A |
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 71.70%, STAA belongs to the best of the industry, outperforming 82.01% of the companies in the same industry.
In the last couple of years the Gross Margin of STAA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for STAA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
STAA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STAA has more shares outstanding
Compared to 5 years ago, STAA has more shares outstanding
The debt/assets ratio for STAA has been reduced compared to a year ago.
2.2 Solvency
STAA has an Altman-Z score of 7.86. This indicates that STAA is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.86, STAA belongs to the best of the industry, outperforming 88.36% of the companies in the same industry.
STAA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.86 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
STAA has a Current Ratio of 4.94. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of STAA (4.94) is better than 77.78% of its industry peers.
STAA has a Quick Ratio of 4.05. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.05, STAA is doing good in the industry, outperforming 76.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.05 |
3. Growth
3.1 Past
STAA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -223.96%.
Measured over the past 5 years, STAA shows a small growth in Earnings Per Share. The EPS has been growing by 7.49% on average per year.
Looking at the last year, STAA shows a decrease in Revenue. The Revenue has decreased by -2.64% in the last year.
Measured over the past years, STAA shows a quite strong growth in Revenue. The Revenue has been growing by 15.88% on average per year.
EPS 1Y (TTM)-223.96%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-52.63%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%6.93%
3.2 Future
STAA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.71% yearly.
STAA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.40% yearly.
EPS Next Y-478.33%
EPS Next 2Y-52.97%
EPS Next 3Y10.63%
EPS Next 5Y22.71%
Revenue Next Year-25.47%
Revenue Next 2Y-2.75%
Revenue Next 3Y1.32%
Revenue Next 5Y4.4%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for STAA. In the last year negative earnings were reported.
Also next year STAA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.97%
EPS Next 3Y10.63%
5. Dividend
5.1 Amount
STAA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.55
-0.08 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners110.7%
Inst Owner Change-3.06%
Ins Owners0.47%
Ins Owner Change0.14%
Market Cap1.31B
Revenue(TTM)313.90M
Net Income(TTM)-95.27M
Analysts52.86
Price Target25.12 (-5.39%)
Short Float %8.18%
Short Ratio4.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.1%
Min EPS beat(2)12.63%
Max EPS beat(2)49.58%
EPS beat(4)3
Avg EPS beat(4)-804.03%
Min EPS beat(4)-3398.76%
Max EPS beat(4)120.44%
EPS beat(8)6
Avg EPS beat(8)-381.38%
EPS beat(12)9
Avg EPS beat(12)-234.3%
EPS beat(16)12
Avg EPS beat(16)-163.13%
Revenue beat(2)2
Avg Revenue beat(2)5.93%
Min Revenue beat(2)3.61%
Max Revenue beat(2)8.25%
Revenue beat(4)2
Avg Revenue beat(4)-6.53%
Min Revenue beat(4)-37.91%
Max Revenue beat(4)8.25%
Revenue beat(8)4
Avg Revenue beat(8)-3.38%
Revenue beat(12)5
Avg Revenue beat(12)-2.03%
Revenue beat(16)6
Avg Revenue beat(16)-1.67%
PT rev (1m)0%
PT rev (3m)28.26%
EPS NQ rev (1m)61.43%
EPS NQ rev (3m)148.35%
EPS NY rev (1m)9.87%
EPS NY rev (3m)29.2%
Revenue NQ rev (1m)-2.63%
Revenue NQ rev (3m)1.45%
Revenue NY rev (1m)-1.22%
Revenue NY rev (3m)0.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.89 | ||
| P/tB | 3.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS4.55
BVpS6.82
TBVpS6.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.76% | ||
| ROE | -28.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 71.7% | ||
| FCFM | N/A |
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
F-Score3
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 180.2% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.05 | ||
| Altman-Z | 7.86 |
F-Score3
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)365.33%
Cap/Depr(5y)348.39%
Cap/Sales(3y)6.49%
Cap/Sales(5y)6.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-223.96%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-52.63%
EPS Next Y-478.33%
EPS Next 2Y-52.97%
EPS Next 3Y10.63%
EPS Next 5Y22.71%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%6.93%
Revenue Next Year-25.47%
Revenue Next 2Y-2.75%
Revenue Next 3Y1.32%
Revenue Next 5Y4.4%
EBIT growth 1Y-410.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-364.34%
EBIT Next 3Y89.45%
EBIT Next 5Y67.63%
FCF growth 1Y-8000.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-281.92%
OCF growth 3Y-29.01%
OCF growth 5Y-9.43%
STAAR SURGICAL CO / STAA FAQ
What is the fundamental rating for STAA stock?
ChartMill assigns a fundamental rating of 4 / 10 to STAA.
What is the valuation status for STAA stock?
ChartMill assigns a valuation rating of 0 / 10 to STAAR SURGICAL CO (STAA). This can be considered as Overvalued.
What is the profitability of STAA stock?
STAAR SURGICAL CO (STAA) has a profitability rating of 3 / 10.
What is the financial health of STAAR SURGICAL CO (STAA) stock?
The financial health rating of STAAR SURGICAL CO (STAA) is 8 / 10.